QYLD vs XBI
Global X Nasdaq 100 Covered Call ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.60% for QYLD.
- • QYLD pays a higher dividend yield (5.94%).
Side-by-side metrics
| Metric | QYLD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.60% | 0.35% |
Dividend yield Trailing 12-month yield. | 5.94% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $8.37B | $10.73B |
YTD return | 8.99% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.49 | 1.10 |
P/E ratio | 32.60 | — |
Last price | $18.40 | $164.01 |
Inception | — | — |
Issuer | Global X | State Street |
QYLD top holdings
| NVDA | NVIDIA Corp | 7.75% |
| AAPL | Apple Inc | 6.80% |
| MU | Micron Technology Inc | 5.75% |
| MSFT | Microsoft Corp | 4.43% |
| AMD | Advanced Micro Devices Inc | 4.18% |
| AMZN | Amazon.com Inc | 4.10% |
| TSLA | Tesla Inc | 3.36% |
| GOOGL | Alphabet Inc Class A | 3.33% |
| INTC | Intel Corp | 3.10% |
| GOOG | Alphabet Inc Class C | 3.08% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About QYLD
QYLD (Global X Nasdaq 100 Covered Call ETF) is Nasdaq-100 covered call income strategy. Managed by Global X, the fund carries $8.4B in assets under management, an expense ratio of 0.60%, a dividend yield of 5.94%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.8% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 10.7%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.